Please wait while the formulary information is being retrieved.
NYSTATIN-TRIAMCINOLONE (nystatin/triamcinolone acetonide)
- Cutaneous candidiasis
100,000 unit/gram-0.1 % topical ointment
- Apply to the affected area(s) by topical route 2 times per day
100,000 unit/g-0.1 % topical cream
- Apply to the affected area(s) by topical route 2 times per day in themorning and evening
Cutaneous candidiasis
- Apply to the affected area(s) by topical route 2 times per day
- Apply to the affected area(s) by topical route 3 times per day
- Apply to the affected area(s) by topical route 2 times per day in themorning and evening
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- Adrenal cortical insufficiency
- No disease contraindications
- Telangiectasia
NYSTATIN-TRIAMCINOLONE (nystatin/triamcinolone acetonide)
- Cutaneous candidiasis
- None
- Erythema
- Stinging of skin
More Frequent
Severe
Less Severe
- Folliculitis
- Purpura
- Skin and skin structure infection
- Skin atrophy
- Headache disorder
- Paresthesia
- Pruritus of skin
- Skin rash
- Telangiectasia
- Treatment site sequelae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adrenal cortical insufficiency
- Bullous dermatitis
- Cataracts
- Central serous chorioretinopathy
- Glaucoma
- Hypothalamic-pituitary insufficiency
- Ocular hypertension
- Skin hypopigmentation
- Skin striae
- Skin ulcer
- Urticaria
Less Severe
- Acneiform eruption
- Alopecia
- Blistering skin
- Contact dermatitis
- Dry skin
- Dyschromia
- Eczema
- Glycosuria
- Hirsutism
- Hypercortisolism
- Hyperesthesia
- Hyperglycemia
- Miliaria
- Perioral dermatitis
- Pruritus of skin
- Skin irritation
- Skin rash
- Treatment site sequelae
Contraindicated
None
Severe Precaution
Triamcinolone Acet (Top,Dental)
Limit use. May be more susceptible to topical steroid-induced HPA-Axis suppression.
- 1 Day – 13 Years
- Limit use. May be more susceptible to topical steroid-induced HPA-Axis suppression.
Management or Monitoring Precaution
None
Nystatin (topical Cream, Oint)
- Severity Level:
C
- Additional Notes: Drug poorly absorbed from intact skin.
Triamcinolone (topical)
- Severity Level:
C
- Additional Notes: Amt of absorption unknown;possible risk of orofacial clefts w/sys corticosteroid
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Triamcinolone (nasal,inh,top,ophth)
Amount of systemic absorption unknown, caution advised
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Amount of systemic absorption unknown, caution advised |
No Known Risk
Nystatin (top, Vag)
Oral drug may be used in neonates.
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | Not known; no or inclusive data | Oral drug may be used in neonates. |
Contraindicated
None
Precaution Exists
Triamcinolone(topical)
Skin-Elderly at increased risk of skin atrophy, ulceration, especially with existing decreased skin circulation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Cutaneous candidiasis | |
| B37.2 | Candidiasis of skin and nail |
| 0-9 | A-Z |
|---|---|
| B37.2 | Candidiasis of skin and nail |
Formulary Reference Tool